Cargando…

Author Correction: Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?

Detalles Bibliográficos
Autores principales:	Qamar, M. A., Sauerbier, A., Politis, M., Carr, H., Loehrer, P. A., Chaudhuri, K. Ray
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898235/ https://www.ncbi.nlm.nih.gov/pubmed/36737446 http://dx.doi.org/10.1038/s41531-023-00464-6

Ejemplares similares

Presynaptic dopaminergic terminal imaging and non-motor symptoms assessment of Parkinson’s disease: evidence for dopaminergic basis?
por: Qamar, MA, et al.
Publicado: (2017)

Non-oral dopaminergic therapies for Parkinson’s disease: current treatments and the future
por: Ray Chaudhuri, K, et al.
Publicado: (2016)

Dysphagia is associated with presynaptic dopaminergic dysfunction and greater non-motor symptom burden in early drug-naïve Parkinson’s patients
por: Polychronis, Sotirios, et al.
Publicado: (2019)

Author Correction: Genetic factors affecting dopaminergic deterioration during the premotor stage of Parkinson disease
por: Lee, Myung Jun, et al.
Publicado: (2022)

Dural Arteriovenous Fistula-Associated Reversible Parkinsonism with Presynaptic Dopaminergic Loss
por: Kim, Hang Rai, et al.
Publicado: (2015)

Author Correction: Regulatory rare variants of the dopaminergic gene ANKK1 as potential risk factors for Parkinson’s disease
por: Pérez‑Santamarina, Estela, et al.
Publicado: (2022)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

Presynaptic Dopaminergic Dysfunction Was Overestimated in Huntington’s Disease Presenting as Young Age-Onset Parkinsonism
por: Kim, Taewon, et al.
Publicado: (2022)

Dopaminergic modulation of motor network dynamics in Parkinson’s disease
por: Michely, Jochen, et al.
Publicado: (2015)

Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinson’s Disease
por: van Wamelen, Daniel J., et al.
Publicado: (2018)

Methodological considerations of evaluating the rate of presynaptic dopaminergic denervation in Parkinson disease with radiotracers: Analysis of the PPMI data
por: Lee, Jeong Won, et al.
Publicado: (2021)

Influence of Depressive Symptoms on Dopaminergic Treatment of Parkinson’s Disease
por: Hanganu, Alexandru, et al.
Publicado: (2014)

Author Correction: A comprehensive map coupling histone modifications with gene regulation in adult dopaminergic and serotonergic neurons
por: Södersten, Erik, et al.
Publicado: (2018)

Parkinson's disease and dopaminergic neurons
Publicado: (2012)

Author Correction: Microglia-specific overexpression of α-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity
por: Bido, Simone, et al.
Publicado: (2021)

Quantified Striatal Dopaminergic Denervation as Predictor for Motor Outcomes in Parkinson's Disease
por: Trinh, Ilene, et al.
Publicado: (2023)

Gait abnormalities and non-motor symptoms predict abnormal dopaminergic imaging in presumed drug-induced Parkinsonism
por: Aamodt, Whitley W., et al.
Publicado: (2022)

Author Correction: Post-treatment with PT302, a long-acting Exendin-4 sustained release formulation, reduces dopaminergic neurodegeneration in a 6-Hydroxydopamine rat model of Parkinson’s disease
por: Chen, Shuchun, et al.
Publicado: (2018)

The range and nature of non-motor symptoms in drug-naive Parkinson’s disease patients: a state-of-the-art systematic review
por: Zis, Panagiotis, et al.
Publicado: (2015)

Dopaminergic Pathway Genes Influence Adverse Events Related to Dopaminergic Treatment in Parkinson's Disease
por: Redenšek, Sara, et al.
Publicado: (2019)

Author Correction: Tick holocyclotoxins trigger host paralysis by presynaptic inhibition
por: Chand, Kirat K., et al.
Publicado: (2022)

Endocannabinoid Modulation of Dopaminergic Motor Circuits
por: Morera-Herreras, Teresa, et al.
Publicado: (2012)

Parkinson’s Disease, the Dopaminergic Neuron and Gammahydroxybutyrate
por: Mamelak, Mortimer
Publicado: (2018)

Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms
por: Dukart, Juergen, et al.
Publicado: (2017)

Dissociable effects of dopaminergic medications on depression symptom dimensions in Parkinson’s disease
por: Costello, Harry, et al.
Publicado: (2023)

Author Correction: MRI-based multivariate gray matter volumetric distance for predicting motor symptom progression in Parkinson's disease
por: Vijayakumari, Anupa A., et al.
Publicado: (2023)

Modulation of flight and feeding behaviours requires presynaptic IP(3)Rs in dopaminergic neurons
por: Sharma, Anamika, et al.
Publicado: (2020)

Impaired brain glucose metabolism and presynaptic dopaminergic functioning in a mouse model of schizophrenia
por: Tomasella, Eugenia, et al.
Publicado: (2020)

Correction to: A microfluidic platform for continuous monitoring of dopamine homeostasis in dopaminergic cells
por: Yu, Yue, et al.
Publicado: (2019)

Author Correction: Common and distinct roles of amygdala subregional functional connectivity in non-motor symptoms of Parkinson’s disease
por: Wang, Junling, et al.
Publicado: (2023)

Exercise Ameliorates Motor Deficits and Improves Dopaminergic Functions in the Rat Hemi-Parkinson’s Model
por: Chen, Yuan-Hao, et al.
Publicado: (2018)

The dopaminergic system supports flexible and rewarding dyadic motor interactive behaviour in Parkinson’s Disease
por: Era, Vanessa, et al.
Publicado: (2022)

Clinical implications for dopaminergic and functional neuroimage research in cognitive symptoms of Parkinson’s disease
por: Hirano, Shigeki
Publicado: (2021)

Vulnerability of Mesostriatal Dopaminergic Neurons in Parkinson's Disease
por: González-Hernández, Tomás, et al.
Publicado: (2010)

Dopaminergic Dysregulation, Artistic Expressiveness, and Parkinson's Disease
por: López-Pousa, S., et al.
Publicado: (2012)

Advances in non-dopaminergic treatments for Parkinson's disease
por: Stayte, Sandy, et al.
Publicado: (2014)

Dopaminergic modulation of emotional conflict in Parkinson's disease
por: Fleury, Vanessa, et al.
Publicado: (2014)

Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease
por: Buddhala, Chandana, et al.
Publicado: (2015)

Ipsilateral deficits of dopaminergic neurotransmission in Parkinson's disease
por: Kaasinen, Valtteri
Publicado: (2015)

Neuromelanin Imaging and Dopaminergic Loss in Parkinson's Disease
por: Isaias, Ioannis U., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_iubl32ifhtm8uc0b7d1pnj3la2